Skip to main content
. Author manuscript; available in PMC: 2021 Jul 22.
Published in final edited form as: Neuropharmacology. 2017 Sep 6;126:190–199. doi: 10.1016/j.neuropharm.2017.09.007

Figure 6.

Figure 6.

Effects of CAB2-015 or BAK4-54 on oral sucrose self-administration. Pretreatment with CAB2-015, but not BAK4-54, dose-dependently inhibited oral sucrose self-administration behavior. N=12/group. *p<0.05, compared to the vehicle control group..